Antibiotics Poised For ‘Breakthrough’-Style Changes At FDA, Venture Capitalist Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Even if FDA already has authorities, legislation can energize agency, Third Rock Ventures’ Borisy tells Senate, adding limited population approval should be extended beyond antibiotics to other disease areas.
You may also be interested in...
FDA Succession Planning Targeted In House Legislation
Hamburg’s departure from commissioner post seems to be proceeding smoothly; proposals in 21st Century Cures bill would mandate a similar process always be followed.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.
Bernie Gets Mostly Pharma-Friendly Drug Pricing Results
Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.